Mizuho analyst Steven Valiquette raised the firm’s price target on McKesson (MCK) to $690 from $630 and keeps a Neutral rating on the shares. McKesson closed its acquisition of Prism Vision on Wednesday, and Mizuho expects the company to close its pending $2.5B majority stake acquisition in Florida Cancer Specialists “soon,” the analyst tells investors in a research note. The firm is modeling 45c-50c accretion from 9-10 months of FCS in the new fiscal 2026 EPS estimate of $37.00.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson price target lowered to $692 from $700 at Deutsche Bank
- McKesson price target raised to $745 from $642 at Morgan Stanley
- McKesson: Strong Performance and Strategic Positioning Drive Buy Rating
- AMD downgraded, Roku reinstated: Wall Street’s top analyst calls
- McKesson price target raised to $691 from $641 at Wells Fargo